Atlas Trials

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Clinical trial NCT06976944 · RECRUITING

Trial details

NCT number
NCT06976944
Sponsor
Yukinori Ozaki
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Triple-Negative Breast Cancer
Start date
2025-06-24
Primary completion
2029-09-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.